Cypher news from FiercePharma
News
FDA panel to mull DTC changes
Brace yourselves: An FDA advisory committee meets today to hash over the possibility of putting a side-effects hotline number in every DTC television commercial. The meeting comes at a time when drug... Read more...
FDA panel: Approve Medtronic stent
Medtronic's new drug-coated stent may soon turn the Boston Scientific-Johnson & Johnson rivalry into a three-way battle for market share. The Minneapolis-based company got an FDA panel's... Read more...
Data backs use of J&J's Cypher stent
On the scales of stent safety, the evidence is piling up in favor of the previously discredited drug-coated models--Johnson & Johnson's Cypher in particular. On top of positive research... Read more...
Little common ground in stent controversy
Bad news first: Heart attack victims are more likely to die if they're fitted with a drug-coated stent than if they're given a bare one, according to an analysis of 2,300 patients in 14 countries,... Read more...
Tough times for stent market
The market for drug-delivering heart stents has been spiraling toward... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
